Bill Text: NY A03842 | 2013-2014 | General Assembly | Introduced


Bill Title: Defines pedigree for prescription drugs as an electronic record containing information regarding each distribution of a prescription drug, originating from a manufacturer, through acquisition by or transfer to one or more wholesalers, manufacturers, or pharmacies, until final sale or transfer to a pharmacy or other person furnishing, administering, or dispensing the prescription drug.

Spectrum: Partisan Bill (Democrat 14-0)

Status: (Introduced - Dead) 2014-01-08 - referred to health [A03842 Detail]

Download: New_York-2013-A03842-Introduced.html
                           S T A T E   O F   N E W   Y O R K
       ________________________________________________________________________
                                         3842
                              2013-2014 Regular Sessions
                                 I N  A S S E M B L Y
                                   January 29, 2013
                                      ___________
       Introduced  by  M.  of  A.  PAULIN,  TITONE,  GOTTFRIED, GALEF, CLARK --
         Multi-Sponsored by --  M.  of  A.  BOYLAND,  COLTON,  COOK,  DINOWITZ,
         HIKIND,  HOOPER,  ORTIZ,  RAIA, ROBINSON, SWEENEY, WRIGHT -- read once
         and referred to the Committee on Health
       AN ACT to amend the public health  law,  in  relation  to  pedigree  for
         prescription drugs
         THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
       BLY, DO ENACT AS FOLLOWS:
    1    Section 1. Section 270 of the public health law is amended by adding a
    2  new subdivision 15 to read as follows:
    3    15. "PEDIGREE"  MEANS  AN  ELECTRONIC  RECORD  CONTAINING  INFORMATION
    4  REGARDING  EACH  TRANSACTION,  RESULTING  IN A CHANGE OF OWNERSHIP, OF A
    5  PRESCRIPTION DRUG, ORIGINATING FROM A MANUFACTURER, THROUGH  ACQUISITION
    6  BY  OR  TRANSFER TO ONE OR MORE WHOLESALERS, MANUFACTURERS, REPACKAGERS,
    7  OR PHARMACIES, UNTIL FINAL SALE OR  TRANSFER  TO  A  PHARMACY  OR  OTHER
    8  PERSON  FURNISHING,  ADMINISTERING, OR DISPENSING THE PRESCRIPTION DRUG,
    9  AS PROVIDED IN SECTION TWO HUNDRED EIGHTY-A OF THIS ARTICLE.
   10    S 2. The public health law is amended by adding a new section 280-a to
   11  read as follows:
   12    S 280-A. PEDIGREE. 1. A. EVERY MANUFACTURER SHALL ESTABLISH AND  MAIN-
   13  TAIN  A PEDIGREE FOR EACH PRESCRIPTION DRUG, AND EVERY WHOLESALER, PHAR-
   14  MACY OR OTHER PERSON FURNISHING OR DISPENSING A PRESCRIPTION DRUG  SHALL
   15  MAINTAIN A PEDIGREE FOR EACH PRESCRIPTION DRUG.
   16    B.  FOR  PURPOSES  OF  THIS SECTION, "MANUFACTURER" MEANS A PERSON WHO
   17  PREPARES, DERIVES, MANUFACTURES, PRODUCES OR REPACKAGES  A  PRESCRIPTION
   18  DRUG. MANUFACTURER ALSO MEANS THE HOLDER OR HOLDERS OF A NEW DRUG APPLI-
   19  CATION (NDA), AN ABBREVIATED NEW DRUG APPLICATION (ANDA), OR A BIOLOGICS
   20  LICENSE  APPLICATION  (BLA),  PROVIDED  THAT  SUCH  APPLICATION HAS BEEN
   21  APPROVED; A MANUFACTURER'S THIRD PARTY  LOGISTICS  PROVIDER;  A  PRIVATE
   22  LABEL  DISTRIBUTOR  (INCLUDING COLICENSED PARTNERS) FOR WHOM THE PRIVATE
   23  LABEL DISTRIBUTOR'S PRESCRIPTION DRUGS ARE ORIGINALLY  MANUFACTURED  AND
        EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                             [ ] is old law to be omitted.
                                                                  LBD03185-03-3
       A. 3842                             2
    1  LABELED  FOR  THE  DISTRIBUTOR  AND  HAVE  NOT  BEEN  REPACKAGED; OR THE
    2  DISTRIBUTOR  AGENT  FOR  THE  MANUFACTURER,  CONTRACT  MANUFACTURER,  OR
    3  PRIVATE  LABEL DISTRIBUTOR, WHETHER THE ESTABLISHMENT IS A MEMBER OF THE
    4  MANUFACTURER'S  AFFILIATED GROUP (REGARDLESS OF WHETHER THE MEMBER TAKES
    5  TITLE TO THE DRUG) OR IS A CONTRACT DISTRIBUTOR SITE.
    6    C. FOR PURPOSES OF THIS SECTION, "REPACKAGER" MEANS A PERSON OR ENTITY
    7  THAT IS REGISTERED WITH THE FEDERAL FOOD AND DRUG  ADMINISTRATION  AS  A
    8  REPACKAGER  AND  OPERATES  AN ESTABLISHMENT THAT PACKAGES FINISHED DRUGS
    9  FROM BULK OR THAT REPACKAGES PRESCRIPTION DRUGS INTO DIFFERENT  CONTAIN-
   10  ERS, EXCLUDING SHIPPING CONTAINERS.
   11    D.  FOR  PURPOSES  OF  THIS  SECTION, "THIRD PARTY LOGISTICS PROVIDER"
   12  MEANS AN ENTITY LICENSED AS A WHOLESALER THAT CONTRACTS WITH A  MANUFAC-
   13  TURER  OF  PRESCRIPTION  DRUGS  TO  PROVIDE  OR  COORDINATE WAREHOUSING,
   14  DISTRIBUTION OR OTHER SIMILAR SERVICES ON BEHALF OF A MANUFACTURER,  BUT
   15  FOR WHICH THERE IS NO CHANGE OF OWNERSHIP IN THE PRESCRIPTION DRUGS.
   16    2.  A  PEDIGREE  SHALL BE IN SUCH FORM AND CONTAIN SUCH INFORMATION AS
   17  SHALL BE DETERMINED BY THE DEPARTMENT IN CONSULTATION WITH  THE  DEPART-
   18  MENT  OF  EDUCATION.  EACH  PEDIGREE  SHALL  MINIMALLY  INCLUDE FOR EACH
   19  DISTRIBUTION ALL OF THE FOLLOWING INFORMATION:
   20    A. THE SOURCE OF THE PRESCRIPTION DRUG, INCLUDING THE NAME AND PRINCI-
   21  PAL ADDRESS OF THE SELLER OR TRANSFEROR;
   22    B. THE PROPRIETARY AND ESTABLISHED NAME OF THE PRESCRIPTION DRUG,  THE
   23  QUANTITY  OF THE PRESCRIPTION DRUG, ITS DOSAGE FORM AND DOSAGE STRENGTH,
   24  THE DATE OF THE PURCHASE OR  TRANSFER,  THE  INVOICE  NUMBER,  CONTAINER
   25  SIZE,  EXPIRATION DATE, LOT NUMBER, NATIONAL DRUG CODE, AND, WHEN AVAIL-
   26  ABLE, STANDARDIZED NUMERICAL IDENTIFIER, OF THE PRESCRIPTION DRUG;
   27    C. THE BUSINESS NAME AND ADDRESS OF EACH  OWNER  OF  THE  PRESCRIPTION
   28  DRUG AND ITS SHIPPING INFORMATION, INCLUDING THE NAME AND ADDRESS OF THE
   29  FACILITY   OF   EACH  PERSON  CERTIFYING  DELIVERY  OR  RECEIPT  OF  THE
   30  PRESCRIPTION DRUG; AND
   31    D. A CERTIFICATION UNDER PENALTY OF PERJURY FROM THE DESIGNATED REPRE-
   32  SENTATIVE OF THE MANUFACTURER, WHOLESALER OR PHARMACY THAT THE  INFORMA-
   33  TION CONTAINED THEREIN IS TRUE AND ACCURATE.
   34    3.  A  SINGLE  PEDIGREE  SHALL  INCLUDE EVERY CHANGE OF OWNERSHIP OF A
   35  PRESCRIPTION DRUG FROM ITS INITIAL  MANUFACTURE  THROUGH  TO  ITS  FINAL
   36  TRANSACTION TO A PHARMACY OR OTHER PERSON FOR FURNISHING, ADMINISTERING,
   37  OR  DISPENSING  THE  PRESCRIPTION  DRUG,  REGARDLESS  OF  REPACKAGING OR
   38  ASSIGNMENT OF ANOTHER NATIONAL DRUG CODE DIRECTORY NUMBER.  PRESCRIPTION
   39  DRUGS  THAT  ARE  REPACKAGED SHALL BE SERIALIZED BY THE REPACKAGER AND A
   40  PEDIGREE SHALL BE PROVIDED THAT REFERENCES THE PEDIGREE OF THE  ORIGINAL
   41  PACKAGE OR PACKAGES PROVIDED BY THE MANUFACTURER.
   42    4. A PEDIGREE SHALL TRACK EACH PRESCRIPTION DRUG AT THE SMALLEST PACK-
   43  AGE OR IMMEDIATE CONTAINER DISTRIBUTED BY THE MANUFACTURER, RECEIVED AND
   44  DISTRIBUTED BY THE WHOLESALER OR REPACKAGER, AND RECEIVED BY THE PHARMA-
   45  CY  OR  ANOTHER  PERSON  FURNISHING,  ADMINISTERING,  OR  DISPENSING THE
   46  PRESCRIPTION DRUG. FOR PURPOSES OF THIS SECTION,  "SMALLEST  PACKAGE  OR
   47  IMMEDIATE   CONTAINER"   OF   A  PRESCRIPTION  DRUG  SHALL  INCLUDE  ANY
   48  PRESCRIPTION DRUG PACKAGE OR CONTAINER MADE AVAILABLE TO  A  REPACKAGER,
   49  WHOLESALER, PHARMACY, OR OTHER ENTITY FOR REPACKAGING OR REDISTRIBUTION,
   50  AS  WELL  AS  THE SMALLEST UNIT MADE BY THE MANUFACTURER FOR SALE TO THE
   51  PHARMACY OR OTHER PERSON FURNISHING, ADMINISTERING,  OR  DISPENSING  THE
   52  DRUG.
   53    5.  ANY  RETURN OF A PRESCRIPTION DRUG TO A WHOLESALER OR MANUFACTURER
   54  SHALL BE DOCUMENTED  ON  THE  SAME  PEDIGREE  AS  THE  TRANSACTION  THAT
   55  RESULTED  IN THE RECEIPT OF THE PRESCRIPTION DRUG BY THE PARTY RETURNING
   56  IT.
       A. 3842                             3
    1    6. THE FOLLOWING TRANSACTIONS ARE EXEMPT FROM  THE  PEDIGREE  REQUIRE-
    2  MENTS CREATED BY THIS SECTION:
    3    A.  AN  INTRACOMPANY  SALE  OR  TRANSFER  OF  A PRESCRIPTION DRUG. FOR
    4  PURPOSES OF THIS SECTION, "INTRACOMPANY  SALE  OR  TRANSFER"  MEANS  ANY
    5  TRANSACTION  FOR  ANY VALID BUSINESS PURPOSE BETWEEN A DIVISION, SUBSID-
    6  IARY, PARENT, OR AFFILIATED OR RELATED COMPANY UNDER THE  COMMON  OWNER-
    7  SHIP AND CONTROL OF THE SAME CORPORATE OR LEGAL ENTITY.
    8    B.  PRESCRIPTION  DRUGS  RECEIVED  BY  THE STATE OR A LOCAL GOVERNMENT
    9  ENTITY FROM A DEPARTMENT OR AGENCY OF THE FEDERAL GOVERNMENT OR AN AGENT
   10  OF  THE  FEDERAL   GOVERNMENT   SPECIFICALLY   AUTHORIZED   TO   DELIVER
   11  PRESCRIPTION DRUGS TO THE STATE OR LOCAL GOVERNMENT ENTITY.
   12    C.  THE PROVISION OF SAMPLES OF PRESCRIPTION DRUGS BY A MANUFACTURER'S
   13  EMPLOYEE TO AN AUTHORIZED PRESCRIBER, PROVIDED THE SAMPLES ARE DISPENSED
   14  WITHOUT CHARGE ONLY TO A PATIENT OF THE PRESCRIBER.
   15    D. (I) A SALE, TRADE, OR TRANSFER OF A RADIOACTIVE  DRUG  BETWEEN  ANY
   16  TWO ENTITIES LICENSED BY THE DEPARTMENT OR THE FEDERAL NUCLEAR REGULATO-
   17  RY COMMISSION.
   18    (II) THE EXEMPTION IN THIS PARAGRAPH SHALL REMAIN IN EFFECT UNLESS THE
   19  DEPARTMENT, IN CONSULTATION WITH THE DEPARTMENT OF EDUCATION, DETERMINES
   20  THAT  THE  RISK  OF COUNTERFEITING OR DIVERSION OF A RADIOACTIVE DRUG IS
   21  SUFFICIENT TO REQUIRE A PEDIGREE, IN WHICH EVENT THE EXEMPTION  IN  THIS
   22  PARAGRAPH  SHALL  BECOME INOPERATIVE AS PROVIDED IN A REGULATION PROMUL-
   23  GATED BY THE DEPARTMENT.
   24    E. THE SALE, TRADE, OR TRANSFER OF A DANGEROUS DRUG THAT IS LABELED BY
   25  THE MANUFACTURER AS "FOR VETERINARY USE ONLY".
   26    F. THE SALE,  TRADE,  OR  TRANSFER  OF  COMPRESSED  MEDICAL  GAS.  FOR
   27  PURPOSES  OF  THIS SECTION, "COMPRESSED MEDICAL GAS" MEANS ANY SUBSTANCE
   28  IN ITS GASEOUS OR CRYOGENIC LIQUID FORM THAT MEETS MEDICAL PURITY STAND-
   29  ARDS AND HAS APPLICATION IN A MEDICAL OR HOMECARE  ENVIRONMENT,  INCLUD-
   30  ING, BUT NOT LIMITED TO, OXYGEN AND NITROUS OXIDE.
   31    G.  THE  SALE,  TRADE,  OR TRANSFER OF SOLUTIONS. FOR PURPOSES OF THIS
   32  SECTION, "SOLUTIONS" MEANS ANY OF THE FOLLOWING:
   33    (I)  THOSE  INTRAVENOUS  PRODUCTS  THAT,  BY  THEIR  FORMULATION,  ARE
   34  INTENDED FOR THE REPLENISHMENT OF FLUIDS AND ELECTROLYTES, SUCH AS SODI-
   35  UM,  CHLORIDE,  AND  POTASSIUM  AND CALORIES, SUCH AS DEXTROSE AND AMINO
   36  ACIDS, OR BOTH.
   37    (II) THOSE INTRAVENOUS PRODUCTS USED TO MAINTAIN  THE  EQUILIBRIUM  OF
   38  WATER AND MINERALS IN THE BODY, SUCH AS DIALYSIS SOLUTIONS.
   39    (III)  PRODUCTS THAT ARE INTENDED FOR IRRIGATION OR RECONSTITUTION, AS
   40  WELL AS STERILE WATER,  WHETHER  INTENDED  FOR  THOSE  PURPOSES  OR  FOR
   41  INJECTION.
   42    H.  PRESCRIPTION  DRUGS  THAT  ARE  PLACED  IN A SEALED PACKAGE WITH A
   43  MEDICAL DEVICE OR MEDICAL SUPPLIES AT THE POINT OF FIRST  SHIPMENT  INTO
   44  COMMERCE  BY  THE  MANUFACTURER AND THE PACKAGE REMAINS SEALED UNTIL THE
   45  DRUG AND DEVICE ARE USED, PROVIDED THAT THE PACKAGE  IS  ONLY  USED  FOR
   46  SURGICAL PURPOSES.
   47    I. A PRODUCT THAT MEETS EITHER OF THE FOLLOWING CRITERIA:
   48    (I) A PRODUCT COMPRISED OF TWO OR MORE REGULATED COMPONENTS, SUCH AS A
   49  DRUG/DEVICE,  BIOLOGIC/DEVICE,  OR  DRUG/DEVICE/BIOLOGIC, THAT ARE PHYS-
   50  ICALLY, CHEMICALLY, OR OTHERWISE COMBINED OR MIXED  AND  PRODUCED  AS  A
   51  SINGLE ENTITY.
   52    (II) TWO OR MORE SEPARATE PRODUCTS PACKAGED TOGETHER IN A SINGLE PACK-
   53  AGE OR AS A UNIT AND COMPRISED OF DRUG AND DEVICE PRODUCTS OR DEVICE AND
   54  BIOLOGICAL PRODUCTS.
   55    7.  IF A MANUFACTURER, WHOLESALER, OR PHARMACY HAS REASONABLE CAUSE TO
   56  BELIEVE THAT A PRESCRIPTION DRUG IN, OR HAVING BEEN IN,  ITS  POSSESSION
       A. 3842                             4
    1  IS  COUNTERFEIT OR THE SUBJECT OF A FRAUDULENT TRANSACTION, THE MANUFAC-
    2  TURER, WHOLESALER, OR PHARMACY  SHALL  NOTIFY  THE  DEPARTMENT  AND  THE
    3  DEPARTMENT OF EDUCATION WITHIN SEVENTY-TWO HOURS OF OBTAINING SUCH KNOW-
    4  LEDGE.  THIS  SUBDIVISION  SHALL APPLY TO ANY PRESCRIPTION DRUG THAT HAS
    5  BEEN SOLD OR DISTRIBUTED IN OR THROUGH THIS STATE.
    6    8. EVERY PEDIGREE SHALL BE MAINTAINED FOR A PERIOD OF THREE YEARS OR A
    7  REASONABLE PERIOD OF TIME AS DETERMINED BY THE COMMISSIONER, IN  CONSUL-
    8  TATION WITH THE DEPARTMENT OF EDUCATION, AND SHALL BE MADE AVAILABLE FOR
    9  INSPECTION, UPON REASONABLE NOTICE, BY THE DEPARTMENT AND THE DEPARTMENT
   10  OF EDUCATION.
   11    9.  A. A PEDIGREE SHALL BE MAINTAINED IN AN ELECTRONIC PEDIGREE TRACK-
   12  ING OR ALTERNATIVE SYSTEM DETERMINED BY THE DEPARTMENT, IN  CONSULTATION
   13  WITH THE DEPARTMENT OF EDUCATION, TO BE FEASIBLE. IN DETERMINING WHETHER
   14  AN  ELECTRONIC  PEDIGREE TRACKING OR ALTERNATIVE SYSTEM IS FEASIBLE, THE
   15  DEPARTMENT, IN CONSULTATION WITH  THE  DEPARTMENT  OF  EDUCATION,  SHALL
   16  CONSIDER WHETHER SUCH SYSTEM OR FORMAT IS:
   17    (I) READILY AVAILABLE WITH RESPECT TO ALL PRESCRIPTION DRUGS,
   18    (II)  IN  A STANDARDIZED NON-PROPRIETARY DATA FORMAT AND ARCHITECTURE,
   19  AND WIDELY AVAILABLE TO MANUFACTURERS,  WHOLESALERS  AND  PHARMACIES  SO
   20  THAT  THE  SYSTEM  OR  FORMAT IS CAPABLE OF BEING USED BY MANUFACTURERS,
   21  WHOLESALERS AND PHARMACIES FROM SALE BY THE MANUFACTURER THROUGH  ACQUI-
   22  SITION  BY  OR  TRANSFER TO A WHOLESALER, MANUFACTURER OR PHARMACY UNTIL
   23  FINAL SALE OR TRANSFER TO A PHARMACY OR OTHER PERSON FURNISHING,  ADMIN-
   24  ISTERING OR DISPENSING THE PRESCRIPTION DRUG, AND
   25    (III) CONSISTENT AND COMPATIBLE WITH FEDERAL REQUIREMENTS FOR AN ELEC-
   26  TRONIC PEDIGREE TRACKING OR ALTERNATIVE SYSTEM AND A STANDARDIZED NUMER-
   27  ICAL IDENTIFIER.
   28    B.  THE  PROVISIONS  OF THIS SECTION SHALL BECOME OPERATIVE ON JANUARY
   29  FIRST, TWO THOUSAND SIXTEEN, WHICH SHALL BE THE PEDIGREE EFFECTIVE DATE;
   30  PROVIDED, HOWEVER, IF AN ELECTRONIC  PEDIGREE  TRACKING  OR  ALTERNATIVE
   31  SYSTEM  IS  NOT FEASIBLE BY THE PEDIGREE EFFECTIVE DATE, THE DEPARTMENT,
   32  IN CONSULTATION WITH THE DEPARTMENT OF EDUCATION, SHALL  ISSUE  ONE-YEAR
   33  EXTENSIONS  OF  THE  PEDIGREE  EFFECTIVE  DATE  UNTIL THE DEPARTMENT, IN
   34  CONSULTATION WITH THE DEPARTMENT OF EDUCATION, DETERMINES SUCH SYSTEM TO
   35  BE FEASIBLE.
   36    10. A. COMMENCING ON JULY FIRST, TWO THOUSAND SIXTEEN, A WHOLESALER OR
   37  OTHER PERSON FURNISHING A PRESCRIPTION DRUG SHALL NOT (I)  SELL,  TRANS-
   38  FER,  DISTRIBUTE,  OR  DELIVER  A  PRESCRIPTION DRUG WITHOUT PROVIDING A
   39  PEDIGREE, OR (II) ACQUIRE A PRESCRIPTION DRUG WITHOUT RECEIVING A  PEDI-
   40  GREE.  IF  AN  ELECTRONIC PEDIGREE TRACKING OR ALTERNATIVE SYSTEM IS NOT
   41  FEASIBLE BY THE PEDIGREE EFFECTIVE DATE, THE DEPARTMENT, IN CONSULTATION
   42  WITH THE DEPARTMENT OF EDUCATION, MAY EXTEND THE  DATE  UPON  WHICH  THE
   43  PROVISIONS  OF  THIS PARAGRAPH SHALL BECOME OPERATIVE AS IT SHALL DETER-
   44  MINE IN ITS DISCRETION.
   45    B. COMMENCING ON JULY FIRST, TWO THOUSAND  SEVENTEEN,  A  PHARMACY  OR
   46  OTHER  PERSON FURNISHING OR DISPENSING A PRESCRIPTION DRUG SHALL NOT (I)
   47  SELL, TRANSFER, DISTRIBUTE,  OR  DELIVER  A  PRESCRIPTION  DRUG  WITHOUT
   48  PROVIDING  A  PEDIGREE,  OR  (II)  ACQUIRE  A  PRESCRIPTION DRUG WITHOUT
   49  RECEIVING A PEDIGREE. IF AN ELECTRONIC PEDIGREE TRACKING OR  ALTERNATIVE
   50  SYSTEM  IS  NOT FEASIBLE BY THE PEDIGREE EFFECTIVE DATE, THE DEPARTMENT,
   51  IN CONSULTATION WITH THE DEPARTMENT OF EDUCATION, MAY  EXTEND  THE  DATE
   52  UPON WHICH THE PROVISIONS OF THIS PARAGRAPH SHALL BECOME OPERATIVE AS IT
   53  SHALL DETERMINE IN ITS DISCRETION.
   54    11.  A. (I) UPON THE EFFECTIVE DATE OF FEDERAL LEGISLATION OR ADOPTION
   55  OF A FEDERAL REGULATION GOVERNING THE FORM OR CONTENT OF PEDIGREE OR THE
   56  STANDARDS AND TECHNOLOGIES FOR THE IDENTIFICATION, VALIDATION,  TRACKING
       A. 3842                             5
    1  AND TRACING AND AUTHENTICATION FOR PRESCRIPTION DRUGS, THE PROVISIONS OF
    2  THIS  SECTION  THAT  ARE  INCONSISTENT  WITH SUCH FEDERAL LEGISLATION OR
    3  FEDERAL REGULATION SHALL BECOME INOPERATIVE.
    4    (II)  WITHIN  NINETY  DAYS  OF THE ENACTMENT OF FEDERAL LEGISLATION OR
    5  ADOPTION  OF  A  FEDERAL  REGULATION  THAT  IS  INCONSISTENT  WITH   THE
    6  PROVISIONS OF THIS SECTION AS PROVIDED IN SUBPARAGRAPH (I) OF THIS PARA-
    7  GRAPH, THE DEPARTMENT SHALL PUBLISH A NOTICE STATING WHICH PROVISIONS OF
    8  THIS SECTION ARE INOPERATIVE. THE DEPARTMENT SHALL HAVE THE AUTHORITY TO
    9  ADOPT  EMERGENCY REGULATIONS AS IT DEEMS NECESSARY, IN CONSULTATION WITH
   10  THE DEPARTMENT OF EDUCATION, IN ITS DETERMINATION TO REFLECT THE INOPER-
   11  ATION OF ANY PROVISION OF THIS SECTION AS PROVIDED IN THIS PARAGRAPH.
   12    B. (I) IF THE FEDERAL FOOD AND DRUG ADMINISTRATION ENACTS ANY RULE  OR
   13  STANDARD  OR  TAKES  ANY  OTHER  ACTION  THAT  IS  INCONSISTENT WITH ANY
   14  PROVISION OF THIS SECTION GOVERNING THE FORM OR CONTENT OF  PEDIGREE  OR
   15  THE  STANDARDS  AND  TECHNOLOGIES  FOR  THE  IDENTIFICATION, VALIDATION,
   16  TRACKING AND TRACING, AND AUTHENTICATION FOR  PRESCRIPTION  DRUGS,  SUCH
   17  PROVISION OF THIS SECTION SHALL BE DEEMED INOPERATIVE.
   18    (II)  WITHIN  NINETY  DAYS OF THE FEDERAL FOOD AND DRUG ADMINISTRATION
   19  ENACTING ANY RULE OR STANDARD OR TAKING ANY OTHER ACTION THAT IS  INCON-
   20  SISTENT  WITH THE PROVISIONS OF THIS SECTION AS PROVIDED IN SUBPARAGRAPH
   21  (I) OF THIS PARAGRAPH, THE DEPARTMENT SHALL  PUBLISH  A  NOTICE  STATING
   22  WHICH  PROVISIONS  OF THIS SECTION ARE INOPERATIVE. THE DEPARTMENT SHALL
   23  HAVE THE AUTHORITY TO ADOPT EMERGENCY REGULATIONS AS IT DEEMS  NECESSARY
   24  IN  ITS DETERMINATION, IN CONSULTATION WITH THE DEPARTMENT OF EDUCATION,
   25  TO REFLECT THE INOPERATION OF ANY PROVISION OF THIS SECTION AS  PROVIDED
   26  IN THIS PARAGRAPH.
   27    12.  A.  ALL UNITS OF PRESCRIPTION DRUGS IN THE POSSESSION OF A WHOLE-
   28  SALER OR PHARMACY FOR WHICH THE MANUFACTURER DOES NOT HOLD  LEGAL  TITLE
   29  ON  THE  PEDIGREE  EFFECTIVE  DATE  SHALL NOT BE SUBJECT TO THE PEDIGREE
   30  REQUIREMENTS SET FORTH IN THIS SECTION; PROVIDED, HOWEVER, IF  ANY  SUCH
   31  UNITS OF PRESCRIPTION DRUGS ARE SUBSEQUENTLY RETURNED TO THE MANUFACTUR-
   32  ER,  THEY  SHALL BE SUBJECT TO THE PEDIGREE REQUIREMENTS IF THE MANUFAC-
   33  TURER DISTRIBUTES SUCH UNITS IN THIS STATE.
   34    B. ALL UNITS OF PRESCRIPTION DRUGS IN THE POSSESSION OF A MANUFACTURER
   35  FOR WHICH THE MANUFACTURER DOES NOT HOLD LEGAL  TITLE  ON  THE  PEDIGREE
   36  EFFECTIVE  DATE  SHALL  NOT  BE SUBJECT TO THE PEDIGREE REQUIREMENTS SET
   37  FORTH IN THIS SECTION.
   38    13. ANY PERSON WHO VIOLATES ANY PROVISION OF  THIS  SECTION  SHALL  BE
   39  SUBJECT  TO  A FINE OF NOT MORE THAN TWO THOUSAND DOLLARS PER VIOLATION.
   40  IN ADDITION, ANY PRESCRIPTION DRUG  DISTRIBUTED,  TRANSFERRED,  ADMINIS-
   41  TERED,  FURNISHED,  OR  DISPENSED  IN VIOLATION OF THIS SECTION SHALL BE
   42  CONTRABAND AND SUBJECT TO SEIZURE EITHER BY THE  DEPARTMENT,  THE  STATE
   43  BOARD OF PHARMACY OR ANY LAW ENFORCEMENT OFFICER OF THE STATE.
   44    S 3. This act shall take effect on the one hundred eightieth day after
   45  it  shall  have  become a law. The department of health, in consultation
   46  with the department of  education,  shall  promulgate  rules  and  regu-
   47  lations,  issue  forms  and take any other action necessary to implement
   48  the provisions of this act on or before the pedigree effective date,  as
   49  provided  in paragraph b of subdivision 9 of section 280-a of the public
   50  health law, as added by section two of this act.
feedback